News

Stacie is a 27-year-old who loves the outdoors. Her journey with pulmonary hypertension began when she was an infant: at just 10 months old, she had double pneumonia. Although she recovered, she became sick again a month later. After visiting an on-call doctor who happened to be a heart specialist, her family…

A subcutaneous infusion of Remodulin (treprostinil) was an effective and tolerable treatment against severe pulmonary hypertension associated with chronic kidney disease in a patient on hemodialysis, according to a case report. The case study “Subcutaneous treprostinil was effective and tolerable in a patient with severe pulmonary hypertension associated with…

Scientists have long known that people with scleroderma are at increased risk of developing pulmonary arterial hypertension. But many with scleroderma whom doctors suspect of having PAH are not receiving optimal screening for the respiratory condition, a study concludes. Nor are enough scleroderma patients suspected of having pulmonary hypertension being referred for tests that…

MannKind Corporation, which is developing the pulmonary arterial hypertension (PAH) therapy Treprostinil Technosphere, has retained the biopharmaceutical financing specialist Locust Walk to help it raise capital for Treprostinil and other projects. Locust Walk lines up investors and strategic partners for companies like MannKind, which also wants to use its Technosphere technology to develop…

Researchers implanted a long-term, intravenous therapy-delivery system consisting of internal pumps and catheters in 60 pulmonary arterial hypertension (PAH) patients, according to a clinical trial. The IV infusion system, developed by Medtronic, delivers Remodulin (treprostinil). The research team said the system should be easier to use than current therapy-delivery methods.

People with chronic thromboembolic pulmonary hypertension (CTEPH) are more likely to have a depressive temperament, finds a Japanese study, “Depressive Status in Patients With Chronic Thromboembolic Pulmonary Hypertension” that appeared in the Circulation Journal. CTEPH is a progressive disease characterized by increasing pulmonary vascular resistance. Although the underlying…

A live, online mini-concert starring Chloe Temtchine has drawn thousands of viewers while raising awareness about pulmonary hypertension (PH), a progressive, life-threatening disease. The Facebook Live concert, presented recently by the Pulmonary Hypertension Association (PHA), attracted 1,500 live attendees and served as the finale for PHA’s World PH Day, the culmination…